Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
‘Real life’ effectiviteit en veiligheid van SOF/VEL/VOX bij HCV na falen op DAA
nov 2019 | Hepatitis